4 de diciembre de 2014 / 16:58 / en 3 años

BUZZ-Bind Therapeutics Inc: Credit Suisse halves price target

** Drug developer's shares down 7 pct at $6.28

** Credit Suisse halves price target to $10, saying it does not expect data from mid-stage trial of prostate cancer drug to be conclusive to support a late-stage trial

** Company's lead drug met the main goal in a mid-stage trial in lung cancer patients.

** Credit Suisse expects data from mid-stage study of the same drug in prostate cancer patients towards year-end or early 2015

** Median price target on stock $20

** Up to Wednesday's close, stock had lost 55 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below